Cadila Healthcare News
Indian drug regulator allows Cadila Healthcare to conduct phase III trials for two-dose COVID-19 vaccine
The company has already received the emergency use authorization from the Drug Controller General of India (DCGI) for ZyCoV-D to be administered in three doses
The Gujarat-based Zydus Cadila has more than 270 USFDA approvals and has filed over 360 abbreviated new drug applications (ANDAs), since it commenced filings in 2003-04
Drug firm Zydus Cadila Thursday said it has received tentative nod from the US health regulator to market generic Sitagliptin and Metformin Hydrochloride extended-release tablets used for controlling blood sugar levels
Drug firm Zydus Cadila on Tuesday said it has received final approval from the US health regulator to market Atenolol and Chlorthalidone tablets USP, used to treat high blood pressure, in the US
Cadila Healthcare, Zydus Wellness to buy Heinz India for Rs 4,595 cr; Complan, Glucon D, Nycil brands part of deal
The transaction is proposed to be financed by a mix of equity and debt
Grafalon offers a specific advantage of efficacy and better safety profile through targeted immunosuppression
The EIR report is given to an establishment after the completion of an inspection by the USFDA
The Ahmedabad-headquartered company received a warning letter for its Moraiya formulation facility and Ahmedabad API facility
Drug firm Cadila Healthcare reported a 52 percent rise in its consolidated net profit to Rs 281.91 crore for the third quarter ended 31 December 2014 on back of robust sales.
According to IMS health the estimated sales in 2014 for Glipizide ER tablets is $90.1 million
Voltas' cooling division is facing increased pressure on the margin front as other players are offering freebies and discounts to liquidate existing inventories.